2010-06-09 14:57 Eisai AB Global EMBRACE-studie jämförde eribulin med behandling enligt läkarens val

2010-06-07 17:11 Eisai AB Global EMBRACE Study Compared Eribulin to Treatment of Physician’s Choice

2010-04-01 12:00 Eisai AB LONDON, UK, 31 March 2010 — Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as ‘E7389’, for the treatment of locally advanced or metastatic breast cancer in Europe.

2009-11-10 07:00 Eisai AB

2009-10-07 13:31 Eisai AB Den store andel af epilepsipatienter, der stadig får anfald trods medicinsk behandling, får nu en ny mulighed for at nedbringe deres anfaldsfrekvens. En ny tillægsbehandling Zebinix (eslicarbazepinacetat) til voksne patienter med partielle anfald giver således mulighed for nedsat anfaldsfrekvens og forhøjet livskvalitet med én pille om dagen.

2009-09-24 13:56 Eisai AB A subsidiary of Eisai Corporation of North America, Morphotek®, Inc., today announced preliminary data from a Phase II trial evaluating the safety and efficacy of farletuzumb in platinum-sensitive epithelial ovarian cancer subjects experiencing their first relapse. Farletuzumab (MORAb-003) is a humanized monoclonal antibody that targets the Folate Receptor Alpha (FRA).

2009-03-12 14:55 Eisai AB Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, today announced that it has commenced a multi-centered Phase II study of its MORAb-009 monoclonal antibody in mesothelioma. The study will evaluate MORAb-009, plus the chemotherapy drugs pemetrexed and cisplatinum, as a first-line treatment for patients with mesothelioma.